Down Syndrome Detection Company Ariosa Diagnostics, Inc. Officially Withdraws IPO; Acquired by Roche

Ariosa Diagnostics, which provides genetic tests that determine fetal conditions and characteristics for expectant mothers, officially withdrew its plans for an initial public offering on Thursday. In December, the company announced its acquisition by Roche for an undisclosed sum. It originally filed terms to raise $60 million in April 2014 at a proposed valuation of $323 million, postponed the IPO, possibly due to patent litigation between it and Illumina ( ILMN ).

Help employers find you! Check out all the jobs and post your resume.

Back to news